Helen McShane

Nov 19, 2024 | nature.com | Andrew White |Shuailin Li |Nacho Aguilo |Carlos Martin |Carlos Martín |Helen McShane | +3 more

AbstractThe only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious than BCG in preclinical models including non-human primates (NHPs), and has demonstrated safety and immunogenicity in human populations.

Feb 26, 2024 | thelancet.com | Helen McShane

1WHOGlobal tuberculosis report 2023. Just one licensed vaccine exists, the live attenuated In 2022, 1·5 million people died of tuberculosis.Mycobacterium bovis Bacille Calmette-Guérin (BCG). BCG protects infants against disseminated disease but most people who have tuberculosis have pulmonary disease and live in low-income and middle-income countries, where the efficacy of BCG is very low. 2Mangtani P Abubakar I Ariti C et al.